Unicycive Therapeutics EBITDA 2020-2025 | UNCY

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Unicycive Therapeutics ebitda from 2020 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Unicycive Therapeutics ebitda from 2020 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$81.7B
Zoetis (ZTS)	$67.1B
Daiichi Sankyo, - (DSNKY)	$46.4B
Takeda Pharmaceutical (TAK)	$45.5B
BeOne Medicines - (ONC)	$32.3B
Sandoz Group AG (SDZNY)	$26.1B
Summit Therapeutics (SMMT)	$20.4B
Merck (MKKGY)	$16.9B
Shionogi (SGIOY)	$15B
United Therapeutics (UTHR)	$13.4B
Neurocrine Biosciences (NBIX)	$13.2B
Orion OYJ (ORINY)	$11.5B
IPSEN (IPSEY)	$10.8B
Stevanato Group S.p.A (STVN)	$7.9B
Corcept Therapeutics (CORT)	$7.3B
Grifols, S.A (GRFS)	$6.9B
Ionis Pharmaceuticals (IONS)	$6.6B
Madrigal Pharmaceuticals (MDGL)	$6.5B
Hikma Pharmaceuticals Plc (HKMPF)	$6.2B
Ono Pharmaceutical (OPHLF)	$5.2B
Soleno Therapeutics (SLNO)	$4.3B
Hypermarcas (HYPMY)	$3B
Crinetics Pharmaceuticals (CRNX)	$2.8B
NewAmsterdam Pharma (NAMS)	$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2B
Ocular Therapeutix (OCUL)	$1.9B
Endo (NDOI)	$1.8B
ARS Pharmaceuticals (SPRY)	$1.8B